Market capitalization | $276.83m |
Enterprise Value | $295.23m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 34.65 |
EV/Sales (TTM) EV/Sales | 1.64 |
P/S ratio (TTM) P/S ratio | 1.54 |
P/B ratio (TTM) P/B ratio | 4.93 |
Revenue growth (TTM) Revenue growth | 15.29% |
Revenue (TTM) Revenue | $180.27m |
As a Free StocksGuide user, you can view scores for all 6,814 stocks worldwide.
5 Analysts have issued a Cerus Corporation forecast:
5 Analysts have issued a Cerus Corporation forecast:
Dec '24 |
+/-
%
|
||
Revenue | 180 180 |
15%
15%
|
|
Gross Profit | 100 100 |
16%
16%
|
|
EBITDA | -33 -33 |
39%
39%
|
EBIT (Operating Income) EBIT | -35 -35 |
38%
38%
|
Net Profit | -21 -21 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Head office | United States |
CEO | Obi Greenman |
Employees | 281 |
Founded | 1991 |
Website | www.cerus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.